Dasatinib-induced immune mediated-thrombotic thrombocytopenic purpura

Demirsoy E., MEHTAP Ö., Atesoglu E. B., TARKUN P., EREN N., Geduk A., ...More

TRANSFUSION AND APHERESIS SCIENCE, no.2, pp.222-224, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Publication Date: 2018
  • Doi Number: 10.1016/j.transci.2018.02.003
  • Journal Name: TRANSFUSION AND APHERESIS SCIENCE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.222-224
  • Keywords: Dasatinib, Thrombotic thromboytopenic purpura, Plasma exchange, Side effect, PATHOGENESIS, LEUKEMIA
  • Kocaeli University Affiliated: Yes

Abstract

Most commonly seen side effects with Tyrosine kinase inhibitors (TKI's) are hematologic toxicities. Besides, with dasatinib autoimmune side effects can be seen. Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that can be related to various causes mainly autoimmune disorders or antineoplastic drugs. Few cases of TKI associated secondary thrombotic microangiopathies (TMA) have been reported in literature. Most of cases were diagnosed as hemolytic uremic syndrome (HUS) rather than TTP. Herein, we describe a 37-year-old CML patient who was diagnosed as immune-mediated TTP related to dasatinib. (C) 2018 Elsevier Ltd. All rights reserved.